Charles M. Quick
Professor
Also affiliated: Twitter (United States) (2013); Cedars-Sinai Medical Center (2017); Brigham and Women's Hospital (2011–2017); Belfast Health and Social Care Trust (2017); Beth Israel Deaconess Medical Center (2017); Cleveland Clinic (2017); Memorial Sloan Kettering Cancer Center (2017); NewYork–Presbyterian Hospital (2017); Kaiser Permanente (2020); The University of Texas MD Anderson Cancer Center (2017); Los Alamos National Laboratory (2012); Harvard University (2013–2017); Baylor College of Medicine (2022); Vanderbilt University (2017–2020); University of Arkansas Medical Center (2012–2023); Emory University Hospital (2017); El Camino Hospital (2017); New York Hospital Queens (2017); University of Alabama at Birmingham (2014); University of Saskatchewan (2018–2023); Yale University (2017); Massachusetts General Hospital (2017); Central Arkansas Veterans Healthcare System (2006–2012); Hattiesburg Clinic (2023); Mills Peninsula Health Services (2017); Perinatal Institute (2012); Winthrop Rockefeller Foundation (2020–2025); Rocky Mountain Cancer Centers (2014); Radiology Associates of Albuquerque (2014); Johns Hopkins Hospital (2017); The US Oncology Network (2014); Clinical Research Associates (2017); Arkansas Department of Agriculture (2015–2019); The University of Texas Southwestern Medical Center (2019–2025); Vanderbilt University Medical Center (2020); Stanford University (2017)
Faculty Researcher
Pathology, College of Medicine
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Charles M. Quick, Professor in the Department of Pathology at the University of Arkansas for Medical Sciences, investigates the molecular characteristics and progression of various gynecologic cancers. His research group has analyzed the integrated mutational landscapes of uterine leiomyosarcomas and poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix. He has also explored the malignant potential of ovarian steroid cell tumors and the recurrent gynandroblastoma of the ovary, including its association with DICER1 mutations.
In addition to his work on uterine and ovarian cancers, Dr. Quick has contributed to research on cervical cancer, including the expansion of human papillomavirus-specific T cells in therapeutic vaccine recipients. His other research interests include the potential link between diabetes and endometriosis in reproductive-age women, and the longitudinal monitoring of tumor response to immune checkpoint inhibitors using diffuse reflectance spectroscopy.
Dr. Quick's scholarship metrics include an h-index of 35, with 183 total publications and 3,958 total citations. He is recognized as a highly cited researcher. His key collaborators include Michael Cho, Yong‐Chen Lu, and Rosalia C. M. Simmen from the University of Arkansas for Medical Sciences, and Narasimhan Rajaram from the University of Arkansas at Fayetteville.
Metrics
- h-index: 36
- Publications: 183
- Citations: 4,001
Selected Publications
-
Hypertrophic Lichen Sclerosus (2026)
-
“Dark Paget” Cells in Extramammary Paget Disease of the Vulva—Diagnostic Features and Interpretative Pitfalls (2026)
-
Abstract 2908: SR-A antagonism remodels the myeloid population of tumor immune microenvironment, expands CD8-positive T cells, and enhances antitumor efficacy in vivo (2026)
-
Polypoid endometriosis with endometrioid intraepithelial neoplasia mimicking malignancy: a rare case of a postmenopausal pelvic mass (2026)
-
986 “Fibrosarcoma-like” Tumors of the Gynecologic Tract Show Overlapping Morphology but Distinct Molecular Subgroups Including Those with Gene Fusions and Recurrent ERBB2/3 Mutations (2026)
-
993 Interobserver Agreement and Diagnostic Certainty in Adenosarcoma (2026)
-
430 Democratizing Continuing Medical Education (CME) Globally by Free, Interactive, Virtual Programming from the International Society of Gynecological Pathologists (ISGyP): Sustainable Engagement by Low-Middle Income Country (LMIC) Pathologists and Trainees between 2021 and 2025 (2026)
-
958 Hypertrophic Lichen Sclerosus: A Form of “Atypical” Lichen Sclerosus in the Pathway to HPV-Independent Squamous Cell Carcinoma of the Vulva (2026)
-
383 “Dark Paget” Cells in Extramammary Paget Disease of the Vulva – Diagnostic Features and Interpretative Pitfalls (2026)
-
931 Leveraging Cloud-Based Whole Slide Imaging for Rare Cancer Repository Building: Uterine Mesenchymal Tumors (2026)
-
Detection of mitochondrial DNA mutations in T cells following 5-FU or cisplatin exposure (2026)
-
Isolation of mitochondrial mutation-specific T cell receptors (2025)
-
Endometrial Carcinogenesis (2025)
-
Principles and Practical Guidelines of Intraoperative Consultation (2025)
-
Germ Cell Tumors and Mixed Germ Cell-Sex Cord-Stromal Tumors of the Ovary (2025)
Collaboration Network
Top Collaborators
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
- Isolation of mitochondrial mutation-specific T cell receptors
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- A Pilot Study on the Co-existence of Diabetes and Endometriosis in Reproductive-Age Women: Potential for Endometriosis Progression
- Endometriosis and Endometriosis-Associated Tumors
- Co-Morbidity of Type 1 Diabetes Promotes Endometriosis Status-A Pilot Study
- Longitudinal monitoring of tumor response to immune checkpoint inhibitors using noninvasive diffuse reflectance spectroscopy
- Investigating the relationship between hypoxia, hypoxia-inducible factor 1, and the optical redox ratio in response to radiation therapy
- Data from Raman Spectroscopy and Machine Learning Reveals Early Tumor Microenvironmental Changes Induced by Immunotherapy
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Abstract 3529: T-cell trafficking and extravasation is suppressed in distal tumors during gastrointestinal tract dysbiosis
- Gynecologic and Obstetric Pathology
- The Malignant Potential of Ovarian Steroid Cell Tumors Revisited
- Ensuring remote diagnostics for pathologists: an open letter to the US Congress
- HPV-associated Vulvar Intraepithelial Carcinoma With Sebaceous Differentiation: Report of 2 Cases
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Interpretation of p16 and p53 in the Classification of Squamous Cell Carcinoma of the Vulva—An Interobserver Agreement Study
- Coexpression of p53 and p16 in Vulvar Squamous Neoplasia
- “Dark Paget” Cells in Extramammary Paget Disease of the Vulva—Diagnostic Features and Interpretative Pitfalls
- Gynecologic and Obstetric Pathology
- The Malignant Potential of Ovarian Steroid Cell Tumors Revisited
- Endometriosis and Endometriosis-Associated Tumors
- Integrated mutational landscape analysis of uterine leiomyosarcomas
- Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix
Similar Researchers
Based on overlapping research topics